{"product_id":"bmy-business-model-canvas","title":"(BMY) Bristol-Myers Squibb Company Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers Squibb’s Business Model, Simplified\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Bristol-Myers Squibb Company’s business model. This Business Model Canvas breaks down how BMS creates value through innovative therapies, key partnerships, and a strong global presence. Ideal for investors, analysts, and strategists who want a clear, actionable view—download the full version to go deeper.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer alliance for Eliquis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb co-developed Eliquis with Pfizer and still shares the economics 50\/50, making it one of its most important alliances. Eliquis remained a multibillion-dollar cardiovascular brand, with 2024 global sales above $13 billion, supporting worldwide commercialization and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2seventy bio cell therapy collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s 2seventy bio link centered on Abecma economics and U.S. commercialization in BCMA CAR-T for multiple myeloma, with Bristol-Myers Squibb Company later buying 2seventy bio for $5.00 a share, or about $286 million, in 2024. It shows Bristol-Myers Squibb Company still needs outside partners to build next-gen oncology assets fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses contract manufacturers and CDMOs to make selected biologics, small molecules, and cell therapy products, helping expand capacity and keep supply steady across launches. In 2024, Bristol-Myers Squibb Company reported $45.0 billion in product sales, so external partners are key for global scale and continuity of supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial sites and CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company depends on hospitals, investigators, and CROs to run global late-stage trials in oncology, immunology, and cardiovascular disease. This matters because Bristol-Myers Squibb Company spent $11.7 billion on R\u0026amp;D in 2024, so patient enrollment, monitoring, and data quality sit at the center of that spend.\u003c\/p\u003e\n\u003cp\u003eThese partners speed site activation and help Bristol-Myers Squibb Company generate clean evidence for regulators and payers. In a portfolio with more than 50 development programs, the trial network is a core execution layer, not a back-office function.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrive global patient enrollment.\u003c\/li\u003e\n\u003cli\u003eSupport safety monitoring and data capture.\u003c\/li\u003e\n\u003cli\u003eEnable late-stage oncology and immunology trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWholesalers, specialty distributors, and access partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company relies on wholesalers, specialty distributors, and access partners to move high-value drugs into pharmacies, clinics, and hospitals, while payers and government buyers shape reimbursement and speed to use. In 2025, this network mattered across a business that generated roughly $46 billion in annual revenue, so even small access wins can shift volume fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWholesalers widen product reach.\u003c\/li\u003e\n\u003cli\u003eSpecialty distributors support complex therapies.\u003c\/li\u003e\n\u003cli\u003ePayers drive reimbursement and uptake.\u003c\/li\u003e\n\u003cli\u003eGovernment buyers affect market access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHow Bristol Myers Squibb Leverages Pfizer and Partners to Power Eliquis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol Myers Squibb depends on Pfizer for Eliquis, where 50\/50 economics still support a $13 billion-plus global brand, and on CDMOs and CROs to scale supply and trials across a business that produced about $46 billion in revenue in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eEliquis economics\u003c\/td\u003e\n\u003ctd\u003e50\/50 share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs, CDMOs\u003c\/td\u003e\n\u003ctd\u003eTrials and supply\u003c\/td\u003e\n\u003ctd\u003e$11.7B R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-world Business Model Canvas for Bristol-Myers Squibb, covering its 9 blocks and key value drivers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps spot Bristol-Myers Squibb’s key pain points and business drivers at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Bristol-Myers Squibb, helping users verify key claims fast and make better decisions with less uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug discovery and preclinical research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses drug discovery and preclinical research to find and test new targets across oncology, hematology, cardiovascular disease, immunology, fibrosis, neuroscience, and infectious disease. Its R\u0026amp;D spend was about $9.3 billion in the latest annual reporting, funding early science that feeds a deep pipeline with 50+ clinical programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development and regulatory submission\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company runs Phase 1 to Phase 3 trials and global filings to build efficacy, safety, and label-expansion data for drugs like Opdivo and Eliquis. In 2025, the company spent about $11 billion on research and development, and faster approvals plus broader labels can lift long-term sales and margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply chain operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company manufactures and ships branded medicines worldwide across small molecules, biologics, and cell therapy, so its supply chain has to stay tight from plant to patient. In FY2025, quality control, serialization, and cold-chain logistics remained core controls for keeping regulated products moving safely and on time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercialization and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses field teams, medical education, and market access work to drive launches, especially in specialty and hospital care, where physician reach and payer access matter most. It also supports doctors with clinical evidence and treatment guidance; in 2024, Bristol-Myers Squibb Company spent $11.8 billion on research and development, which feeds that medical- affairs engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField teams drive adoption\u003c\/li\u003e\n\u003cli\u003eEvidence supports physician use\u003c\/li\u003e\n\u003cli\u003eAccess work opens reimbursement\u003c\/li\u003e\n\u003cli\u003eLaunches matter in hospitals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAlliance management and lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s key activities include managing alliances, royalties, and co-commercial deals across its portfolio, while extending product life with new indications, formulations, and combo uses. This protects cash from mature brands and helps fund launches; in 2025, BMS still faced heavy patent pressure, so this work mattered.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtects mature-brand revenue\u003c\/li\u003e\n\u003cli\u003eShares risk through partnerships\u003c\/li\u003e\n\u003cli\u003eSupports new launches fast\u003c\/li\u003e\n\u003cli\u003eExpands labels and formulations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS: $11B R\u0026amp;D fuels a 50+ program drug pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s key activities are drug discovery, clinical development, and global regulatory filings across oncology, hematology, immunology, cardiovascular, and neuroscience. In FY2025, R\u0026amp;D was about $11 billion, supporting a pipeline with 50+ clinical programs.\u003c\/p\u003e\n\u003cp\u003eIt also runs manufacturing, quality control, and cold-chain distribution for branded medicines, plus field sales, medical education, and payer access work to support launches and label expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~$11 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e50+ \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore focus\u003c\/td\u003e\n\u003ctd\u003eOncology, immunology, cardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Bristol-Myers Squibb Company Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a mockup or sample—this is a live snapshot of the final file, formatted the same way and ready to use. Once you complete your order, you’ll unlock the full version with the same content, layout, and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved branded medicines portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s approved branded portfolio still does the heavy lifting: Eliquis, Opdivo, Revlimid, Pomalyst\/Imnovid, Orencia, Yervoy, and Breyanzi drove most of its $48 billion-plus 2025 revenue base, with Eliquis alone still above $13 billion in annual sales. These brands give Bristol-Myers Squibb Company scale, repeat prescribing, and stronger negotiating power with payers and providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D and development capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s global R\u0026amp;D engine uses thousands of scientists, clinicians, and trial specialists to move assets across oncology, immunology, hematology, and cardiovascular care. Its R\u0026amp;D spend was about $10.8 billion in 2024, and that scale helps support new labels and a steady late-stage pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company relies on a global manufacturing base for drug substance, fill-finish, and specialty biologics; in 2024, it generated about $48 billion in revenue, so this network is central to keeping supply steady. Quality systems, validation, and cGMP facilities protect product integrity and help BMS meet regulator expectations across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntellectual property and regulatory exclusivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol Myers Squibb Company relies on patents, manufacturing know-how, and approved product labels to protect key medicines like oncology and immunology therapies. Regulatory exclusivity, such as orphan-drug and biologic rights, helps keep margins intact until generics or biosimilars can enter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePatents shield core molecules and methods.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLabels lock in approved uses and dosing.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExclusivity delays price erosion.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProtection matters most in high-value therapies.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific talent and external data assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company depends on deep scientific talent in medicinal chemistry, immunology, oncology, and cell therapy, plus clinical datasets and real-world evidence to sharpen trial design and market access. In FY2024, Bristol-Myers Squibb Company generated $48.3 billion in revenue and invested about $11.5 billion in R\u0026amp;D, showing how heavily it funds these resources.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized science drives pipeline quality.\u003c\/li\u003e\n\u003cli\u003eClinical data improves go\/no-go calls.\u003c\/li\u003e\n\u003cli\u003eReal-world evidence strengthens positioning.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers’ Powerhouse Brands Drive a $48B+ Revenue Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s key resources are its branded drugs, especially Eliquis, Opdivo, and Revlimid, which anchored a $48 billion-plus 2025 revenue base. It also depends on a large R\u0026amp;D engine, global biologics manufacturing, and patent and label protection to defend cash flow and keep new assets moving.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eLatest figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue base\u003c\/td\u003e\n\u003ctd\u003e$48B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis annual sales\u003c\/td\u003e\n\u003ctd\u003e$13B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~$10.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad portfolio across high-burden diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company spans 7 therapeutic areas: oncology, hematology, cardiovascular disease, immunology, fibrosis, neuroscience, and infectious disease. That breadth lowers reliance on any one market and gives prescribers more choices across the same company, while Bristol-Myers Squibb Company still generated $48.3 billion in net sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven outcomes in specialty care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEliquis, Opdivo, and Reblozyl anchor Bristol-Myers Squibb Company’s specialty-care value proposition: each has approved labels and large clinical programs, with Eliquis at about $13.3B and Opdivo at about $9.3B in 2024 sales, while Reblozyl reached about $1.8B. \u003c\/p\u003e\n\u003cp\u003eThat proof on efficacy, safety, and differentiation matters because prescribing and reimbursement often follow measurable outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading oncology and hematology franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s oncology and hematology franchise spans Opdivo, Yervoy, Revlimid, Pomalyst\/Imnovid, and Breyanzi, giving it reach across immuno-oncology, multiple myeloma, and cellular therapy. In 2024, Opdivo still brought in about $7 billion in annual sales, and the mix supports cross-selling in specialty cancer centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConvenient oral and outpatient therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s value here is simple: several major medicines are taken by mouth, including Eliquis, Revlimid, Pomalyst\/Imnovid, Zeposia, Sprycel, Inrebic, and Onureg, so patients can avoid infusion visits and often get treated in outpatient care. In 2025, Eliquis remained one of the Company’s top revenue drivers, showing how widely used oral therapy can scale adoption and support adherence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral dosing lowers visit burden\u003c\/li\u003e\n\u003cli\u003eOutpatient use broadens access\u003c\/li\u003e\n\u003cli\u003eAdherence can improve with simpler care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvanced therapies for difficult-to-treat patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s value is strongest in severe, high-need diseases where patients have few options or relapse after prior therapy. Breyanzi is a key example: it topped $1 billion in 2024 sales and extends BMS into hard-to-treat blood cancers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets relapsed, high-risk patients\u003c\/li\u003e\n\u003cli\u003eUses specialty, high-value therapies\u003c\/li\u003e\n\u003cli\u003eBest fit: severe unmet need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers’ Power Trio Drives $48.3B in 2024 Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company’s value lies in proven, high-need therapies across oncology, hematology, and cardiovascular care, with 2024 net sales of $48.3 billion. Eliquis, Opdivo, and Reblozyl anchor the offer: about $13.3 billion, $9.3 billion, and $1.8 billion in 2024 sales, backed by approved labels and large clinical data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eValue Signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003e$13.3B\u003c\/td\u003e\n\u003ctd\u003eOral, broad use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdivo\u003c\/td\u003e\n\u003ctd\u003e$9.3B\u003c\/td\u003e\n\u003ctd\u003eOncology anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReblozyl\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003ctd\u003eSpecialty growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician-led prescribing support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company depends on physicians to choose therapies, so its customer relationships center on clinical data, education, and field medical teams. In specialty care, where treatments can cost tens of thousands of dollars a year, strong doctor ties help drive prescribing and patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management for hospitals and systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company keeps direct ties with hospital systems, oncology centers, and large provider networks because these accounts shape formulary access and treatment paths. In 2024, Bristol-Myers Squibb Company reported $48.3 billion in net sales, showing how much revenue depends on winning long-cycle, high-stakes accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support and adherence programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses patient support to help people start and stay on therapy, especially for chronic specialty drugs like Eliquis and Opdivo. In 2025, the U.S. Medicare Part D out-of-pocket cap was $2,000, so reimbursement help, education, and follow-up can still matter a lot for access and adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharmacovigilance and safety monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company keeps post-market safety surveillance active after approval, with adverse-event reporting running through routine use; this matters most for immunotherapies and cell therapies, where risks can change after launch. Safety monitoring is a core customer relationship because it protects patients and supports label updates, risk management, and regulator follow-up across the product life cycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing adverse-event reporting after approval\u003c\/li\u003e\n\u003cli\u003eCritical for immunotherapies and cell therapies\u003c\/li\u003e\n\u003cli\u003eSupports safer routine use and label changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePayer and reimbursement engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company works closely with insurers, pharmacy benefit managers, and public payers to secure access and coverage, because those rules drive utilization, prior authorization, and patient cost sharing. Access management is a core commercial task in U.S. and global markets, where even small coverage changes can shift patient uptake fast.\u003c\/p\u003e\n\u003cp\u003eThis payer work matters most in high-cost specialty therapies, where formulary placement and step edits can decide whether patients start or stay on treatment. The goal is simple: keep coverage broad enough that access does not stall at the pharmacy counter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShape formulary access and coverage\u003c\/li\u003e\n\u003cli\u003eManage prior authorization friction\u003c\/li\u003e\n\u003cli\u003eInfluence patient out-of-pocket costs\u003c\/li\u003e\n\u003cli\u003eSupport access in public and private plans\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMS Leans on Access, Evidence, and Support to Drive Uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company builds customer ties through evidence, field medical teams, patient support, and payer access work. In 2024, net sales were $48.3 billion, and in 2025 the U.S. Medicare Part D out-of-pocket cap was $2,000, so coverage help still drives uptake and adherence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e$48.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Medicare Part D cap\u003c\/td\u003e\n\u003ctd\u003e$2,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey relationship focus\u003c\/td\u003e\n\u003ctd\u003eDoctors, payers, patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers and distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company relies on large wholesalers and distributors, with U.S. medicines moving mainly through McKesson, Cencora, and Cardinal Health into pharmacy and provider networks. In 2025, Bristol-Myers Squibb Company reported $48.3 billion in net sales, and this channel remains key for broad market reach and fast inventory flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies handle most oral outpatient fills for Bristol-Myers Squibb Company, while specialty pharmacies manage complex, high-cost products like oncology and immunology drugs. In the U.S., retail outlets still fill about 90% of prescription scripts, but specialty pharmacies now serve a much smaller script share while carrying a far larger share of drug spend, so they matter for fulfillment, counseling, and refill control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and clinics are key for Bristol-Myers Squibb Company’s oncology, infusion, and cell therapy sales because many therapies are started and monitored in specialty care. In 2024, Bristol-Myers Squibb Company posted $48.3 billion in revenue, and institutional formulary wins in these settings can decide how fast high-cost drugs reach patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGovernment and institutional procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company sells to government health systems and public procurement programs, especially outside the U.S. and in hospitals. Tendering and centralized buying can swing volumes and force price cuts, so this channel can grow access fast but keep margins tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment buyers drive large, lumpy orders.\u003c\/li\u003e\n\u003cli\u003eTenders can lower net pricing.\u003c\/li\u003e\n\u003cli\u003eInstitutional access expands patient reach.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eField sales and medical education teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses field reps and medical science liaisons to explain product data, trial results, and payer access for complex specialty drugs. This matters most in oncology and immunology, where prescriber support can shape uptake; in 2025, Bristol-Myers Squibb Company reported about $46.2 billion in revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect support for prescribers\u003c\/li\u003e\n\u003cli\u003eShares trial and access details\u003c\/li\u003e\n\u003cli\u003eBest for specialty therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBristol-Myers Squibb’s Sales Flow Through Key U.S. and Global Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses wholesalers, specialty pharmacies, hospitals, and government buyers to move 2025 net sales of $48.3 billion across the U.S. and global markets. Oral drugs flow mainly through retail and specialty pharmacies, while oncology and infusion products depend more on hospitals, clinics, and centralized public tenders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eBroad U.S. reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eComplex therapies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eOncology and infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment buyers\u003c\/td\u003e\n\u003ctd\u003eLarge tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191729889545,"sku":"bmy-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/BMY-business-model-canvas.webp?v=1783678193","url":"https:\/\/dcfanalyst.com\/products\/bmy-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}